The frontotemporal disorders therapy market size is anticipated to reach a valuation of US$ 451.4 million by the end of 2028, based on the company’s most recent study. With an average annual growth rate of 4.7% through 2028, the frontotemporal disorders therapeutic market research indicates enormous expansion potential.
Over the course of the forecast period, the frontotemporal disorders treatment market is likely to rise at a significant rate due to the increased funding for research and development that governments around the world are expected to provide. The National Institute of Ageing (NIA), the National Institute of Neurological Disorders and Strokes (NINDS), and the National Institute of Health (NIH) are government agencies that support research and development as well as efforts to advance the development of neurological disease therapies. The population base of frontotemporal dementia has grown due to the increasing number of dementia cases, and this is predicted to drive up demand for frontotemporal dementia treatments and drugs. An other significant aspect anticipated to fuel the frontotemporal disease therapy market’s expansion is the increasing life expectancy rate. The market for frontotemporal disorders therapy is anticipated to increase at a faster rate due to the numerous non-profit organisations dedicated to drug discovery. The promotion of FTD research activities has been aided by financing initiatives for research undertaken by non-profit organisations such as CurePSP, Inc., Alzheimer Discovery Foundation (ADDF), Bluefield Project Organisation, Tau Consortium Organisation, and Association for Frontotemporal Degeneration (AFTD).
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-5033
However, lack of approved drugs for frontotemporal disorder treatment is expected to negatively impact the growth of the frontotemporal disorders treatment market. Moreover, the high failure rate of clinical trials and studies is also a major factor expected to hamper the growth of the frontotemporal disorders treatment market.
The company has segmented the global frontotemporal disorders treatment market based on drug class, treatment type, disease indication, distribution channel, and regions. Based on drug class, the frontotemporal disorders treatment market is segmented into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. The cognitive enhancers segment is expected to contribute high revenue share in global frontotemporal disorders treatment market. By treatment type, the frontotemporal disorders treatment market is segmented into behavioral symptom management and psychological symptoms management segment. The behavioral symptom management segment is expected to contribute high value share in the global frontotemporal disorders treatment market. Based on disease indication, the frontotemporal disorders treatment market is segmented into frontotemporal dementia, primary progressive aphasia, and movement disorders segment. In terms of revenue, the frontotemporal dementia segment is projected to hold significant share in the global frontotemporal disorders treatment market over the forecast period. Based on distribution channels, the frontotemporal disorders treatment market is segmented into hospital pharmacies, retail pharmacy, drug stores, and online pharmacy. The retail pharmacy segment is expected to contribute high value share in the global frontotemporal disorders treatment market.
On the basis of region, the global frontotemporal disorders treatment market has been segmented into North America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Latin America and the Middle East & Africa. Western Europe is expected to contribute large revenue share in the global frontotemporal disorders treatment market over the forecast period. The demand for frontotemporal disorders treatment has increased in Western Europe due to the increasing prevalence of frontotemporal dementia as well as growing number of clinical studies in the region. North America is expected to contribute second large revenue share in the global frontotemporal disorders treatment market. The Asia Pacific Excluding Japan (APEJ) is projected to witness significant growth due to increasing per capita expenditure and government initiatives for the treatment of neurological disorders.
The report tracks some of the key manufacturers operating in the global frontotemporal disorders treatment market. The players included in the report are Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, GlaxoSmithKline Plc., Novartis AG, Mylan N.V., Merck & Company, Inc., AstraZeneca plc, and Allergen plc, among others.
Key Companies:
- Pfizer Inc.
- Johnson & Johnson
- Sanofi S.A.
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- Novartis AG
- Mylan N.V.
- Merck & Company, Inc.
- AstraZeneca plc.
- Allergen plc
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-5033
Key Segments:
By Drug Class:
- Cognitive Enhancers
- Antipsychotics
- Antidepressants
- CNS Stimulants
- Others
By Treatment:
- Behavioral Symptoms Management
- Psychological Symptoms Management
By Disease Indication:
- Frontotemporal Dementia
- Primary Progressive Aphasia
- Movement Disorders
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region:
- North America Frontotemporal Disorders Treatment Market
- Latin America Frontotemporal Disorders Treatment Market
- Europe Frontotemporal Disorders Treatment Market
- East Asia Frontotemporal Disorders Treatment Market
- South Asia & Pacific Frontotemporal Disorders Treatment Market
- Middle East & Africa (MEA) Frontotemporal Disorders Treatment Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
